These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 39137033)

  • 1. Dual 5-HT
    Oguma T; Jino K; Nakahara K; Asada H; Fuchino K; Nagatani K; Kouki K; Okamoto R; Takai N; Koda K; Fujita S; Sekiguchi Y; Yasuo K; Mayumi K; Abe A; Imono M; Horiguchi N; Iwata S; Kusakabe KI
    J Med Chem; 2024 Aug; 67(16):14478-14492. PubMed ID: 39137033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel aminotetralin-type serotonin (5-HT) 2C receptor-specific agonist and 5-HT2A competitive antagonist/5-HT2B inverse agonist with preclinical efficacy for psychoses.
    Canal CE; Morgan D; Felsing D; Kondabolu K; Rowland NE; Robertson KL; Sakhuja R; Booth RG
    J Pharmacol Exp Ther; 2014 May; 349(2):310-8. PubMed ID: 24563531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's disease.
    McFarland K; Price DL; Bonhaus DW
    Behav Pharmacol; 2011 Oct; 22(7):681-92. PubMed ID: 21921840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of action of pimavanserin in Parkinson's disease psychosis: targeting serotonin 5HT2A and 5HT2C receptors.
    Stahl SM
    CNS Spectr; 2016 Aug; 21(4):271-5. PubMed ID: 27503570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new class of 5-HT
    Casey AB; Mukherjee M; McGlynn RP; Cui M; Kohut SJ; Booth RG
    Br J Pharmacol; 2022 Jun; 179(11):2610-2630. PubMed ID: 34837227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment Possibilities for Psychosis in Parkinson's Disease with An Emphasis on the Newly Approved Drug: Pimavanserin.
    Majlath Z; Obal I; Vecsei L
    CNS Neurol Disord Drug Targets; 2017; 16(3):234-243. PubMed ID: 27719624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atypical antipsychotics and inverse agonism at 5-HT2 receptors.
    Sullivan LC; Clarke WP; Berg KA
    Curr Pharm Des; 2015; 21(26):3732-8. PubMed ID: 26044975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, Synthesis, Molecular Docking, and Biological Evaluation of Novel Pimavanserin-Based Analogues as Potential Serotonin 5-HT
    Albujuq NR; Meana JJ; Diez-Alarcia R; Muneta-Arrate I; Naqvi A; Althumayri K; Alsehli M
    J Med Chem; 2023 Jul; 66(13):9057-9075. PubMed ID: 37378639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving the treatment of Parkinson's disease: Structure-based development of novel 5-HT
    Ma M; Yang Y; Du G; Dai Y; Zhu X; Wang W; Xu H; Zhang J; Zheng L; Zou F; Yang H; Liu B; Liu W; Ye L; Zhang R; Tian J
    Eur J Med Chem; 2022 Apr; 234():114246. PubMed ID: 35279606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pimavanserin exhibits serotonin 5-HT
    Muneta-Arrate I; Diez-Alarcia R; Horrillo I; Meana JJ
    Eur Neuropsychopharmacol; 2020 Jul; 36():83-89. PubMed ID: 32517960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pimavanserin, a novel antipsychotic for management of Parkinson's disease psychosis.
    Kianirad Y; Simuni T
    Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1161-1168. PubMed ID: 28817967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pimavanserin: novel pharmacotherapy for Parkinson's disease psychosis.
    Sahli ZT; Tarazi FI
    Expert Opin Drug Discov; 2018 Jan; 13(1):103-110. PubMed ID: 29047301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pimavanserin, a 5HT
    Yuede CM; Wallace CE; Davis TA; Gardiner WD; Hettinger JC; Edwards HM; Hendrix RD; Doherty BM; Yuede KM; Burstein ES; Cirrito JR
    J Neurochem; 2021 Mar; 156(5):658-673. PubMed ID: 33278025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pimavanserin: An Inverse Agonist Antipsychotic Drug.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2016 Jun; 54(6):21-4. PubMed ID: 27245248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On the discovery and development of pimavanserin: a novel drug candidate for Parkinson's psychosis.
    Hacksell U; Burstein ES; McFarland K; Mills RG; Williams H
    Neurochem Res; 2014 Oct; 39(10):2008-17. PubMed ID: 24682754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel 6,7,8,9-tetrahydro-5H-1,4,7,10a-tetraaza-cyclohepta[f]indene analogues as potent and selective 5-HT(2C) agonists for the treatment of metabolic disorders.
    Tye H; Mueller SG; Prestle J; Scheuerer S; Schindler M; Nosse B; Prevost N; Brown CJ; Heifetz A; Moeller C; Pedret-Dunn A; Whittaker M
    Bioorg Med Chem Lett; 2011 Jan; 21(1):34-7. PubMed ID: 21146986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents.
    Cheng J; Giguère PM; Onajole OK; Lv W; Gaisin A; Gunosewoyo H; Schmerberg CM; Pogorelov VM; Rodriguiz RM; Vistoli G; Wetsel WC; Roth BL; Kozikowski AP
    J Med Chem; 2015 Feb; 58(4):1992-2002. PubMed ID: 25633969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pimavanserin for the treatment of Parkinson's disease psychosis.
    Chendo I; Ferreira JJ
    Expert Opin Pharmacother; 2016 Oct; 17(15):2115-24. PubMed ID: 27609312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pimavanserin for the treatment of Parkinson's disease psychosis.
    Friedman JH
    Expert Opin Pharmacother; 2013 Oct; 14(14):1969-75. PubMed ID: 24016069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pimavanserin.
    Hunter NS; Anderson KC; Cox A
    Drugs Today (Barc); 2015 Nov; 51(11):645-52. PubMed ID: 26744739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.